10-Q: ADC Therapeutics Q3 Loss Widens Amid Restructuring

ADC Therapeutics reported a wider net loss in Q3 2025, driven by restructuring costs, despite strong clinical trial data for ZYNLONTA and successful capital raises.

Summary

• Net loss for the nine months ended September 30, 2025, was $136.2 million, compared to $127.1 million for the same period in 2024.
• Total revenue for the nine months increased by 8.1% to $58.3 million, primarily due to a $5.0 million license revenue milestone from Health Canada approval for ZYNLONTA.
• Product revenues from ZYNLONTA decreased by 3.1% to $51.2 million for the nine months, mainly due to lower sales volume.
• The company initiated a strategic restructuring plan on June 11, 2025, involving the closure of its UK facility and a 30% global workforce reduction, incurring $13.5 million in related costs for the nine months.
• Cash and cash equivalents stood at $234.7 million as of September 30, 2025, with an additional $57.6 million net proceeds from an October 2025 private placement.
• Clinical trials for ZYNLONTA showed promising results: LOTIS-5 (2L+ DLBCL) had an 80% ORR and 50% CR in safety run-in, and LOTIS-7 (r/r B-NHL) achieved a 93.3% ORR and 86.7% CR.
• Investigator-initiated trials for ZYNLONTA in Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) also reported high ORR and CR rates.

Sentiment

Score: 6

Explanation: While the company reported wider losses and decreased product revenue, the successful capital raises and strong clinical trial data for ZYNLONTA's expansion opportunities provide a positive counter-balance. The restructuring, though costly in the short term, aims to improve long-term efficiency and focus. The overall sentiment is cautiously optimistic, reflecting ongoing financial challenges but also significant progress in pipeline development and funding.

Positives

• Total revenue increased by 8.1% to $58.3 million for the nine months ended September 30, 2025, compared to $53.9 million in the prior year.
• License revenues and royalties significantly increased by 583.4% to $7.1 million for the nine months, driven by a $5.0 million milestone payment for ZYNLONTA's conditional approval by Health Canada.
• LOTIS-5 confirmatory Phase 3 trial safety run-in showed an 80% Overall Response Rate (ORR) and 50% Complete Response (CR) rate in 2L+ DLBCL patients.
• LOTIS-7 Phase 1b trial demonstrated a 93.3% ORR and 86.7% CR rate in relapsed or refractory B-NHL patients, including 5 out of 6 CAR-T pre-treated patients achieving CR.
• Investigator-initiated trials (IITs) for ZYNLONTA in Marginal Zone Lymphoma (MZL) reported an 84.6% ORR and 69.2% CR, with 12-month PFS of 92.9%.
• IITs for ZYNLONTA in combination with rituximab in Follicular Lymphoma (FL) showed a 98.2% ORR and 83.6% CR, with median PFS not reached and 12-month PFS of 93.9%.
• Successful completion of a $100.0 million private placement in June 2025 (net proceeds $93.1 million) and a subsequent $60.0 million private placement in October 2025 (net proceeds $57.6 million), bolstering liquidity.

Negatives

• Net loss widened to $136.2 million for the nine months ended September 30, 2025, from $127.1 million in the prior year.
• Product revenues, net, decreased by 3.1% to $51.2 million for the nine months, primarily due to lower sales volume.
• Operating expenses increased by 6.4% to $161.9 million for the nine months, largely due to $13.5 million in restructuring, impairment, and other related costs.
• Net cash used in operating activities increased to $110.1 million for the nine months, up from $102.0 million in the prior year.
• Interest income decreased by 33.0% to $6.5 million for the nine months, due to lower yields and average cash balances.
• The company incurred $13.5 million in restructuring, impairment, and other related costs for the nine months ended September 30, 2025, including severance and asset impairment.
• The Phase 1/2 ADCT 602 clinical trial was discontinued in the second quarter of 2025, and early development efforts for other preclinical solid tumor programs are being discontinued.

Risks

• Substantial net losses have been incurred since inception, and losses are expected to continue, requiring additional capital.
• Ability to raise additional capital depends on financial, economic, and market conditions, authorized shares, and other factors beyond control.
• Indebtedness under the Loan Agreement with Oaktree Capital Management and Owl Rock Capital Advisors LLC includes restrictive covenants.
• The HCR Agreement negatively affects cash generation from ZYNLONTA sales and licensing, and attractiveness as an acquisition target.
• Ability to complete clinical trials on expected timelines, or at all, is uncertain.
• Undesirable side effects or adverse events of products and product candidates could impact commercialization and regulatory approval.
• Ability to obtain and maintain regulatory approval for products and product candidates is not guaranteed.
• Successful commercialization of products by the company and its partners is not assured.
• Availability and scope of coverage and reimbursement for products may be limited.
• Manufacturing of products and product candidates is complex and difficult.
• Substantial competition exists in the industry, including new technologies and therapies.
• Ability to fund or partner early research programs, and the timing, results, and future clinical outcomes of such programs, are uncertain.
• Reliance on third parties for preclinical studies, clinical trials, manufacturing, storage, distribution, and commercialization activities.
• Ability to obtain, maintain, and protect intellectual property rights and operate without infringing on others' rights.
• Estimates regarding future revenue, expenses, liquidity, capital resources, and financing needs may be inaccurate.
• The size and growth potential of markets for products and product candidates may be smaller than anticipated.
• Potential for product liability lawsuits and product recalls.
• The success of the strategic restructuring plan, including estimated costs for workforce reduction and UK facility closure, is not guaranteed and may change.
• Uncertainties of international trade policies, including tariffs, sanctions, and trade barriers, could impact business, financial condition, and results of operations.
• Changes in drug pricing policies, such as potential Most Favored Nation (MFN) pricing, could substantially reduce ZYNLONTA's U.S. list price and negatively impact U.S. product sales revenue and market opportunity.

Future Outlook

The company expects to provide topline data from the LOTIS-5 confirmatory Phase 3 trial in the first half of 2026, with potential confirmatory approval for ZYNLONTA in 2L+ DLBCL and publication/compendia inclusion in the first half of 2027. More mature data from the LOTIS-7 trial is anticipated by the end of 2025, followed by engagement with the FDA and potential publication/compendia inclusion in the first half of 2027. Costs associated with IND-enabling activities for the PSMA-targeting ADC asset are expected to wind down by the end of 2025. The company believes its current cash and capital resources, supplemented by recent capital raises, are sufficient to fund operations for at least the next twelve months.

Management Comments

• We believe that our current cash position and capital resources are sufficient to fund our operation and meet capital requirements for at least the next twelve months from the date of this report.

Industry Context

ADC Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on Antibody Drug Conjugates (ADCs) for cancer treatment. The company's flagship product, ZYNLONTA, targets diffuse large B-cell lymphoma (DLBCL), a market with significant unmet needs, particularly in relapsed or refractory settings. The ongoing clinical trials (LOTIS-5, LOTIS-7) and investigator-initiated trials (MZL, FL) aim to expand ZYNLONTA's indications and market penetration, aligning with the industry trend of developing targeted therapies and combination regimens. The strategic restructuring reflects a common industry practice of prioritizing pipeline assets and optimizing operational efficiency in response to market dynamics and financial pressures. The development of a next-generation PSMA-targeting ADC indicates a continued focus on innovation within the ADC space, a rapidly evolving area of oncology.

Comparison to Industry Standards

• The 80% ORR and 50% CR in the LOTIS-5 safety run-in for 2L+ DLBCL patients are strong indicators, especially considering the median age of 74.5 years and prior therapies. For comparison, other approved therapies in this setting, such as CAR-T cell therapies (e.g., Yescarta, Kymriah) or other ADCs (e.g., Polivy), have shown varying response rates, but direct comparison requires full trial data.
• The 93.3% ORR and 86.7% CR in LOTIS-7 for r/r B-NHL with ZYNLONTA plus glofitamab (a bispecific antibody) are very high, particularly the CR rate. This combination therapy approach is a key trend in oncology, aiming to improve efficacy over monotherapy. For example, other bispecific antibodies like Epkinly (epcoritamab) or Lunsumio (mosunetuzumab) in similar patient populations have shown CR rates in the range of 30-60% as monotherapy or in combination, suggesting ZYNLONTA's combination could be highly competitive.
• The 12-month PFS of 93.9% for ZYNLONTA + rituximab in r/r FL from IIT data is exceptionally high. For context, standard treatments for relapsed FL often show 12-month PFS rates in the 60-80% range, making this a potentially significant improvement if confirmed in larger trials.
• The 12-month PFS of 92.9% for ZYNLONTA monotherapy in r/r MZL from IIT data is also very strong, as MZL is an indolent lymphoma. This compares favorably to other approved agents for MZL, which typically show lower PFS rates.

Legal Proceedings

• The company is not aware of any legal matters for which the likelihood of a loss is probable and reasonably estimable and which could have a material impact on its consolidated financial condition, liquidity, or results of operations.

Related Party Transactions

• The company has a deferred royalty obligation with certain entities managed by HealthCare Royalty Management, LLC (HCR) for up to $325.0 million, which impacts cash generation.
• The company has a senior secured term loan agreement with certain affiliates and/or funds managed by Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC.

Stakeholder Impact

• Shareholders: Impacted by dilution from recent private placements, ongoing net losses, but also potential upside from successful clinical trial outcomes and ZYNLONTA expansion.
• Employees: Affected by a 30% global workforce reduction as part of the 2025 Restructuring plan.
• Patients: Potential for expanded treatment options with ZYNLONTA in earlier lines of DLBCL, MZL, and FL, and future PSMA-targeting ADC.
• Creditors (Oaktree, Owl Rock, HCR): Ongoing interest and royalty payments, with the company's ability to meet obligations tied to ZYNLONTA sales and future financing.
• Suppliers/Partners: Continued reliance on third parties for manufacturing, clinical trials, and commercialization activities.

Next Steps

• Provide topline data from the LOTIS-5 confirmatory Phase 3 clinical trial in the first half of 2026.
• Submit a supplemental Biologics License Application (sBLA) for ZYNLONTA in 2L+ DLBCL, with potential confirmatory approval, publication, and compendia inclusion in the first half of 2027.
• Share more mature data from the LOTIS-7 trial through a corporate update by the end of 2025.
• Engage with the U.S. Food and Drug Administration (FDA) regarding LOTIS-7 data and pursue publication and compendia inclusion in the first half of 2027.
• Assess regulatory and updated compendia pathways for ZYNLONTA in Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) as soon as sufficient data are available.
• Continue to incur research and development costs in connection with ongoing ZYNLONTA clinical trials.
• Wind down costs associated with IND-enabling activities for the PSMA-targeting ADC asset by the end of 2025.
• Pay the remainder of restructuring costs by the first quarter of 2026.

Key Dates

Recommendation

ADC Therapeutics presents a mixed financial picture with widening net losses and declining core product revenue, offset by successful capital raises and promising clinical data for ZYNLONTA's expanded indications. The strategic restructuring, while incurring short-term costs, aims to streamline operations and focus on key assets. The strong clinical results for ZYNLONTA in various lymphoma settings, particularly the high ORR/CR rates in LOTIS-7 and IITs, suggest significant long-term potential. However, the company's continued cash burn and reliance on further financing, coupled with competitive and regulatory risks, warrant a cautious approach. A 'hold' recommendation reflects the balance between the significant clinical upside and the ongoing financial challenges and execution risks.

Keywords

ADC Therapeutics, ADCT, ZYNLONTA, loncastuximab tesirine-lpyl, Antibody Drug Conjugates, ADCs, DLBCL, Diffuse Large B-cell Lymphoma, PSMA-targeting ADC, Oncology, Hematology, Clinical Trials, LOTIS-5, LOTIS-7, Marginal Zone Lymphoma, Follicular Lymphoma, Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Restructuring, Capital Raise